Document Detail


Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis.
MedLine Citation:
PMID:  22202711     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The pleiotropic effects of statins, 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor, have been shown to modify inflammatory cell signaling on the immune response to infection. It was postulated that statins may be a good candidate as novel therapeutic agents for the treatment of sepsis. We investigated whether ongoing statin therapy is associated with mortality in patients with bloodstream infection.
DESIGN: A retrospective cohort study.
SETTING: Two tertiary hospitals in Bronx, NY.
PATIENTS: Adult patients in the hospital with bloodstream infection and categorized according to statin therapy as an outpatient or inpatient before bacteremia.
INTERVENTIONS: None.
MEASUREMENT AND MAIN RESULTS: Of 2,139 bacteremic hospitalized patients, 592 (28%) received statins before blood cultures and 677 (32%) died within 90 days. On multivariate adjustment, the association between statin therapy and 90-day all-cause mortality was statistically significant (hazard ratio, 0.78; 95% confidence interval [CI] 0.65-0.94), but statin users and nonusers differed significantly on many baseline clinical factors. Using the propensity score matched analysis to balance the differences between groups, the association was no longer significant (hazard ratio 0.99; 95% CI 0.77-1.25). Multivariate analysis after stratifying by decile in propensity score for statin use demonstrated similar results (hazard ratio 0.86; 95% CI 0.70-1.06). Statin use was not associated with reduced intensive care unit admission (odds ratio [OR], 0.86; 95% CI 0.59-1.26), hospital length of stay (β = -0.8 days; 95% CI -2.2 to 1.7 days), intensive care unit length of stay (β = -0.1 days; 95% CI -3.7 to 3.8 days), or need for mechanical or noninvasive ventilation (OR 1.03; 95% CI 0.70-1.51).
CONCLUSION: After adjusting for the propensity to receive statin therapy, no statistically significant association between statin therapy before bloodstream infection and survival was identified.
Authors:
Sharon Leung; Reha Pokharel; Michelle N Gong
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Critical care medicine     Volume:  40     ISSN:  1530-0293     ISO Abbreviation:  Crit. Care Med.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-19     Completed Date:  2012-05-07     Revised Date:  2014-09-19    
Medline Journal Info:
Nlm Unique ID:  0355501     Medline TA:  Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1064-71     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Bacteremia / drug therapy*,  mortality
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Intensive Care / statistics & numerical data
Male
Middle Aged
Propensity Score
Proportional Hazards Models
Respiration, Artificial / statistics & numerical data
Retrospective Studies
Statistics, Nonparametric
Treatment Outcome
Grant Support
ID/Acronym/Agency:
HL084060/HL/NHLBI NIH HHS; HL086667/HL/NHLBI NIH HHS; R01 HL084060/HL/NHLBI NIH HHS; R01 HL084060-05/HL/NHLBI NIH HHS; R01 HL086667/HL/NHLBI NIH HHS; R01 HL086667-05/HL/NHLBI NIH HHS; UL1 RR025750/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comments/Corrections
Comment In:
Crit Care Med. 2012 Apr;40(4):1336-7   [PMID:  22425827 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systemic human orbital fat-derived stem/stromal cell transplantation ameliorates acute inflammation ...
Next Document:  A comparison of critical care research funding and the financial burden of critical illness in the U...